MDXG
Price
$6.11
Change
+$0.17 (+2.86%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
877.35M
36 days until earnings call
PRME
Price
$2.46
Change
+$0.03 (+1.24%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
317.73M
37 days until earnings call
Interact to see
Advertisement

MDXG vs PRME

Header iconMDXG vs PRME Comparison
Open Charts MDXG vs PRMEBanner chart's image
MiMedx Group
Price$6.11
Change+$0.17 (+2.86%)
Volume$16.14K
Capitalization877.35M
Prime Medicine
Price$2.46
Change+$0.03 (+1.24%)
Volume$27.81K
Capitalization317.73M
MDXG vs PRME Comparison Chart in %
Loading...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDXG vs. PRME commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDXG is a Buy and PRME is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (MDXG: $5.94 vs. PRME: $2.42)
Brand notoriety: MDXG and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDXG: 279% vs. PRME: 219%
Market capitalization -- MDXG: $877.35M vs. PRME: $317.73M
MDXG [@Biotechnology] is valued at $877.35M. PRME’s [@Biotechnology] market capitalization is $317.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDXG’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • MDXG’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, MDXG is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDXG’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 6 bullish TA indicator(s).

  • MDXG’s TA Score: 5 bullish, 2 bearish.
  • PRME’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MDXG is a better buy in the short-term than PRME.

Price Growth

MDXG (@Biotechnology) experienced а +2.24% price change this week, while PRME (@Biotechnology) price change was +16.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.68%. For the same industry, the average monthly price growth was +32.84%, and the average quarterly price growth was +6.72%.

Reported Earning Dates

MDXG is expected to report earnings on Aug 05, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+3.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDXG($877M) has a higher market cap than PRME($318M). PRME YTD gains are higher at: -17.123 vs. MDXG (-38.254). MDXG has higher annual earnings (EBITDA): 62.1M vs. PRME (-200M). PRME has more cash in the bank: 144M vs. MDXG (106M). MDXG has less debt than PRME: MDXG (18.7M) vs PRME (121M). MDXG has higher revenues than PRME: MDXG (352M) vs PRME (3.85M).
MDXGPRMEMDXG / PRME
Capitalization877M318M276%
EBITDA62.1M-200M-31%
Gain YTD-38.254-17.123223%
P/E Ratio22.00N/A-
Revenue352M3.85M9,152%
Total Cash106M144M74%
Total Debt18.7M121M15%
FUNDAMENTALS RATINGS
MDXG vs PRME: Fundamental Ratings
MDXG
PRME
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
82100
SMR RATING
1..100
4198
PRICE GROWTH RATING
1..100
8537
P/E GROWTH RATING
1..100
12100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (50) in the null industry is in the same range as MDXG (66) in the Biotechnology industry. This means that PRME’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that MDXG’s stock grew similarly to PRME’s over the last 12 months.

MDXG's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for PRME (98) in the null industry. This means that MDXG’s stock grew somewhat faster than PRME’s over the last 12 months.

PRME's Price Growth Rating (37) in the null industry is somewhat better than the same rating for MDXG (85) in the Biotechnology industry. This means that PRME’s stock grew somewhat faster than MDXG’s over the last 12 months.

MDXG's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for PRME (100) in the null industry. This means that MDXG’s stock grew significantly faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDXGPRME
RSI
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 4 days ago
85%
MACD
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
78%
Bullish Trend 4 days ago
74%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 14 days ago
80%
Bearish Trend 19 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMMMX41.000.21
+0.51%
Victory Integrity Discovery Member
PNAIX78.300.37
+0.47%
T. Rowe Price All-Cap Opportunities-I
WCMGX30.820.13
+0.42%
First Trust WCM Focused Global Gr Inst
STSEX2536.802.41
+0.10%
BlackRock Exchange BlackRock
PDRDX11.77-0.01
-0.08%
Principal Diversified Real Asset Instl

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-8.68%
CRSP - PRME
63%
Loosely correlated
+1.69%
RXRX - PRME
57%
Loosely correlated
-6.85%
BEAM - PRME
56%
Loosely correlated
-1.98%
CRBU - PRME
53%
Loosely correlated
-5.19%
CCCC - PRME
51%
Loosely correlated
-7.89%
More